Headlands Technologies LLC Takes Position in Edwards Lifesciences Corporation (NYSE:EW)

Headlands Technologies LLC acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 668 shares of the medical research company’s stock, valued at approximately $48,000.

A number of other large investors have also recently added to or reduced their stakes in EW. Brighton Jones LLC bought a new stake in Edwards Lifesciences during the fourth quarter worth $266,000. Bank Pictet & Cie Europe AG raised its holdings in shares of Edwards Lifesciences by 16.7% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company’s stock valued at $757,000 after purchasing an additional 1,463 shares during the period. Townsquare Capital LLC lifted its stake in Edwards Lifesciences by 24.8% in the 4th quarter. Townsquare Capital LLC now owns 6,501 shares of the medical research company’s stock valued at $481,000 after purchasing an additional 1,293 shares during the last quarter. CreativeOne Wealth LLC bought a new position in Edwards Lifesciences during the fourth quarter worth about $201,000. Finally, Ontario Teachers Pension Plan Board bought a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $1,453,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW opened at $76.95 on Wednesday. The firm has a market cap of $45.18 billion, a PE ratio of 11.07, a price-to-earnings-growth ratio of 3.77 and a beta of 1.08. Edwards Lifesciences Corporation has a 52-week low of $64.00 and a 52-week high of $83.00. The business’s 50 day moving average price is $77.11 and its two-hundred day moving average price is $74.26. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the firm earned $0.70 earnings per share. Edwards Lifesciences’s revenue was up 11.9% on a year-over-year basis. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, VP Daveen Chopra sold 1,500 shares of the stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total value of $112,620.00. Following the transaction, the vice president directly owned 33,496 shares in the company, valued at $2,514,879.68. This trade represents a 4.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares of the company’s stock, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 17,134 shares of company stock valued at $1,311,745. 0.34% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on EW. Wall Street Zen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Robert W. Baird increased their target price on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a “neutral” rating in a research note on Friday, July 25th. Stifel Nicolaus boosted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, July 25th. Evercore ISI increased their price objective on Edwards Lifesciences from $77.00 to $80.00 and gave the stock an “in-line” rating in a research report on Friday, July 25th. Finally, Mizuho lifted their target price on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $85.90.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.